These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31663136)

  • 1. Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib.
    Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Clin Endocrinol (Oxf); 2020 Jan; 92(1):71-76. PubMed ID: 31663136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.
    Ahn J; Song E; Oh HS; Song DE; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Jun; 29(6):824-829. PubMed ID: 30864902
    [No Abstract]   [Full Text] [Related]  

  • 3. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.
    Jin M; Kim M; Jeon MJ; Kim EY; Shin DY; Kim BH; Kim WB; Shong YK; Lim DJ; Kim WG
    Endocrine; 2023 Aug; 81(2):298-305. PubMed ID: 36928602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
    Cheng L; Fu H; Jin Y; Sa R; Chen L
    Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
    Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.
    Ha Y; Mohamed Ali MA; Petersen MM; Harmsen WS; Therneau TM; Lee HC; Ryoo BY; Bampoh S; Valles KA; Mady M; Missula VR; Prasai K; Roberts LR; Kim KM
    Hepatol Int; 2020 Sep; 14(5):776-787. PubMed ID: 32740886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
    Zhou C; Duan D; Liu S
    Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.
    Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Kuwahara C
    Cancer Diagn Progn; 2021; 1(5):491-498. PubMed ID: 35403154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
    Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
    Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Significance of Absolute Lymphocyte Count, Absolute Monocyte Count, and Absolute Lymphocyte Count to Absolute Monocyte Count Ratio in Follicular Non-Hodgkin Lymphoma.
    Mohsen A; Taalab M; Abousamra N; Mabed M
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e606-e615. PubMed ID: 32303487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of lymphocyte-to-monocyte ratio in angioimmunoblastic T cell lymphoma].
    Niu JY; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Wu JZ; Li JY; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):265-270. PubMed ID: 29779318
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.
    Lee SF; Ng TY; Spika D
    BMC Cancer; 2019 Apr; 19(1):338. PubMed ID: 30971203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
    Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
    Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.
    Lin ZX; Ruan DY; Li Y; Wu DH; Ma XK; Chen J; Chen ZH; Li X; Wang TT; Lin Q; Wen JY; Wu XY
    World J Gastroenterol; 2015 Oct; 21(38):10898-906. PubMed ID: 26478681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Low Lymphocyte-to-Monocyte Ratio Predicts Poor Clinical Outcomes for Patients with Urothelial Carcinoma of the Upper Urinary Tract.
    Zhang XK; Yang P; Zhang ZL; Hu WM; Cao Y
    Urol J; 2018 Nov; 15(6):348-354. PubMed ID: 30033515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
    Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
    Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
    Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
    Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.